396 related articles for article (PubMed ID: 14667227)
21. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
[TBL] [Abstract][Full Text] [Related]
22. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
Mai A; Massa S; Cerbara I; Valente S; Ragno R; Bottoni P; Scatena R; Loidl P; Brosch G
J Med Chem; 2004 Feb; 47(5):1098-109. PubMed ID: 14971890
[TBL] [Abstract][Full Text] [Related]
23. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
25. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V
Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448
[TBL] [Abstract][Full Text] [Related]
27. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB
Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213
[TBL] [Abstract][Full Text] [Related]
28. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
Ragno R; Mai A; Massa S; Cerbara I; Valente S; Bottoni P; Scatena R; Jesacher F; Loidl P; Brosch G
J Med Chem; 2004 Mar; 47(6):1351-9. PubMed ID: 14998325
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
[TBL] [Abstract][Full Text] [Related]
30. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
[TBL] [Abstract][Full Text] [Related]
31. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
Chen L; Wilson D; Jayaram HN; Pankiewicz KW
J Med Chem; 2007 Dec; 50(26):6685-91. PubMed ID: 18038969
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.
Su H; Nebbioso A; Carafa V; Chen Y; Yang B; Altucci L; You Q
Bioorg Med Chem; 2008 Sep; 16(17):7992-8002. PubMed ID: 18701301
[TBL] [Abstract][Full Text] [Related]
33. Structure-based optimization of click-based histone deacetylase inhibitors.
Hou J; Feng C; Li Z; Fang Q; Wang H; Gu G; Shi Y; Liu P; Xu F; Yin Z; Shen J; Wang P
Eur J Med Chem; 2011 Aug; 46(8):3190-200. PubMed ID: 21621883
[TBL] [Abstract][Full Text] [Related]
34. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
Thaler F; Colombo A; Mai A; Amici R; Bigogno C; Boggio R; Cappa A; Carrara S; Cataudella T; Fusar F; Gianti E; di Ventimiglia SJ; Moroni M; Munari D; Pain G; Regalia N; Sartori L; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C; Varasi M
J Med Chem; 2010 Jan; 53(2):822-39. PubMed ID: 20017493
[TBL] [Abstract][Full Text] [Related]
36. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
Moradei OM; Mallais TC; Frechette S; Paquin I; Tessier PE; Leit SM; Fournel M; Bonfils C; Trachy-Bourget MC; Liu J; Yan TP; Lu AH; Rahil J; Wang J; Lefebvre S; Li Z; Vaisburg AF; Besterman JM
J Med Chem; 2007 Nov; 50(23):5543-6. PubMed ID: 17941625
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
Dallavalle S; Cincinelli R; Nannei R; Merlini L; Morini G; Penco S; Pisano C; Vesci L; Barbarino M; Zuco V; De Cesare M; Zunino F
Eur J Med Chem; 2009 May; 44(5):1900-12. PubMed ID: 19084294
[TBL] [Abstract][Full Text] [Related]
38. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
Salmi-Smail C; Fabre A; Dequiedt F; Restouin A; Castellano R; Garbit S; Roche P; Morelli X; Brunel JM; Collette Y
J Med Chem; 2010 Apr; 53(8):3038-47. PubMed ID: 20218673
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors.
Zhang Y; Feng J; Liu C; Fang H; Xu W
Bioorg Med Chem; 2011 Aug; 19(15):4437-44. PubMed ID: 21733698
[TBL] [Abstract][Full Text] [Related]
40. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.
Lu Q; Wang DS; Chen CS; Hu YD; Chen CS
J Med Chem; 2005 Aug; 48(17):5530-5. PubMed ID: 16107152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
